Compass Pathways has announced that its investigational psilocybin therapy, COMP360, met the primary endpoint in its Phase 3 ...

A single dose of a synthetic, proprietary formulation of psilocybin (COMP360) was found to improve symptoms in patients with treatment-resistant ...

The leading Post-Traumatic Stress Disorder Companies such as Tonix Pharmaceuticals, Inc., Pop Test Oncology LLC, H. Lundbeck ...